-
公开(公告)号:US20090076260A1
公开(公告)日:2009-03-19
申请号:US12298714
申请日:2007-04-26
申请人: Jyrki Kuusisto , Heikki Heikkila , Matti Tylli , Martin Golde , Teppo Riihimaki
发明人: Jyrki Kuusisto , Heikki Heikkila , Matti Tylli , Martin Golde , Teppo Riihimaki
IPC分类号: C07H1/00
CPC分类号: C07C29/141 , C07B2200/07 , C07H15/04 , C07C31/26
摘要: The invention relates to an improved process for the production of a sugar alcohol from the corresponding sugar through catalytic hydrogenation. Especially, the invention relates to a process for reducing the interference of sugar-derived aldonic acids in the hydrogenation process by adjusting the hydrogenation conditions so that the activity of the catalyst is maintained. In one embodiment of the invention, the process of the invention is carried out by adjusting the hydrogenation temperature by starting the hydrogenation at a lower temperature and then gradually rising the temperature to the final hydrogenation temperature. In another embodiment of the invention, the process of the invention is carried out by adding small-molecular monocarboxylic acids to the hydrogenation solution.
摘要翻译: 本发明涉及通过催化氢化从相应的糖生产糖醇的改进方法。 特别地,本发明涉及通过调节氢化条件来降低加氢过程中糖衍生的醛糖酸的干扰从而保持催化剂的活性的方法。 在本发明的一个实施方案中,本发明的方法是通过在较低温度下开始氢化并随后逐渐升温至最终氢化温度来调节氢化温度来进行的。 在本发明的另一个实施方案中,本发明的方法是通过向氢化溶液中加入小分子单羧酸来进行的。
-
公开(公告)号:US20080031922A1
公开(公告)日:2008-02-07
申请号:US11631873
申请日:2005-07-05
申请人: Teppo Riihimaki
发明人: Teppo Riihimaki
CPC分类号: A61K31/565 , A61K9/0024 , A61K9/0034 , A61K9/0036 , A61K9/0039 , A61K31/58
摘要: The present invention relates to a delivery system comprising a core and a membrane encasing said core, wherein said core and mem-brane consist essentially of an elastomer composition and said core comprises at least one therapeutically active agent. The delivery system is characterized in that the membrane comprises at least one regulating agent. The invention also relates to a method for controlling the release of at least one therapeutically active agent from a delivery system.
摘要翻译: 本发明涉及包含核心和包裹所述核心的膜的递送系统,其中所述核心和组分基本上由弹性体组合物组成,并且所述核心包含至少一种治疗活性剂。 递送系统的特征在于,膜包括至少一种调节剂。 本发明还涉及用于控制至少一种治疗活性剂从递送系统释放的方法。
-